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ABSTRACT
Introduction The primary aim of the National Institute 
of Health Research- funded global health research group, 
Warwick- India- Canada (WIC), is to reduce the burden 
of psychotic disorders in India. India has a large pool of 
undetected and untreated patients with psychosis and a 
treatment gap exceeding 75%. Evidence- based packages 
of care have been piloted, but delivery of treatments 
still remains a challenge. Even when patients access 
treatment, there is minimal to no continuity of care. The 
overarching ambition of WIC programme is to improve 
patient outcomes through (1) developing culturally 
tailored clinical interventions, (2) early identification and 
timely treatment of individuals with mental illness and 
(3) improving access to care by exploiting the potential of 
digital technologies.
Methods and analysis This multicentre, multicomponent 
research programme, comprising five work packages 
and two cross- cutting themes, is being conducted at 
two sites in India: Schizophrenia Research Foundation, 
Chennai (South India) and All India Institute of Medical 
Sciences, New Delhi (North India). WIC will (1) develop 
and evaluate evidence- informed interventions for early 
and first- episode psychosis; (2) determine pathways of 
care for early psychosis; (3) investigate the efficacy and 
cost- effectiveness of community care models, including 
digital and mobile technologies; (4) develop strategies to 
reduce the burden of mental illnesses among youth; (5) 
assess the economic burden of psychosis on patients and 
their carers; and (6) determine the feasibility of an early 
intervention in psychosis programme in India.
Ethics and dissemination This study was approved 
by the University of Warwick’s Biomedical and Scientific 
Research Ethics Committee (reference: REGO-2018-
2208), Coventry, UK and research ethics committees 
of all participating organisations. Research findings 
will be disseminated through peer- reviewed scientific 
publications, presentations at learnt societies and visual 
media.
INTRODUCTION
Globally, psychotic disorders such as schizo-
phrenia are among the top 20 leading 
contributors to disability.1 Nearly 80% of 
individuals develop their first episode of 
psychosis (FEP) during adolescence or 
early adulthood.2 Importantly, the burden 
of disease and disability is particularly high 
in low/middle- income countries (LMICs).3 
LMICs have predominantly young popula-
tions, with the bulk of FEP cases receiving 
inadequate care.3–5 Despite efforts to develop 
healthcare models for accessible and effective 
care in LMICs, the implementation of such 
models remains a major challenge.6
In the developed world, among the most 
significant reforms since deinstitutionali-
sation has been the establishment of early 
intervention in psychosis services (EIS).7 
Given their clinical effectiveness and cost- 
effectiveness,8–10 many countries have 
scaled up EIS as part of their mental health 
policy. EIS focus on reducing the duration 
of untreated psychosis (DUP), provision of 
holistic and evidence- based specialist care 
Strengths and limitations of this study
 ► Warwick- India- Canada (WIC) will develop a bespoke 
clinical interventions with proven efficacy that is 
culturally adapted, appropriate, accessible and 
acceptable.
 ► This is the first multisite study to identify barriers, 
facilitators and economic evaluation for implement-
ing early intervention services in psychosis in India.
 ► WIC will build research capacity with potential for 
future efforts, including in methodologies such as 
health economic evaluation and implementation 
science.
 ► WIC will identify pathways to mental healthcare in 
India and develop community- based models for 
continuity of clinical care.
 ► Some studies embedded are exploratory and 
hypothesis- generating; therefore, large studies may 
be warranted for conclusive evidence.
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during the ‘critical period’ of 2–5 years around onset 
of psychosis and interventions for individuals who are 
at high risk of developing a psychotic disorder (clinical 
high risk or ultra- high risk).11 12 Despite such promising 
evidence, many LMICs have not implemented EIS into 
their mental health systems. Inadequate mental health 
workforce, fragmented healthcare systems13 and scarcity 
of research and implementation capacity are significant 
barriers to introducing such care in LMICs.14 15 Further-
more, DUP is significantly higher in LMICs,16 and there-
fore EIS provision adapted to LMIC settings is potentially 
of great value. Help- seeking in LMICs is often pluralistic, 
with traditional practitioners being the initial and some-
times the only source of care.17 Therefore, a simple ‘trans-
plantation’ of the ‘Western’ EIS model to LMIC context is 
neither feasible nor practical. However, it may be possible 
to incorporate the principles and therapeutic compo-
nents of EIS into locally contextualised mental healthcare 
in LMICs,.3 18 This is the key premise underpinning the 
WIC project.
Aim and strategic goals
The National Institute of Health Research (NIHR) Global 
Health Research Group (GHRG) on Psychosis Outcomes: 
the Warwick- India- Canada (WIC) network aims to reduce 
the burden of psychotic disorders and improve health, 
well- being and functioning of those with psychotic disor-
ders in India. The WIC network brings together knowl-
edge and expertise of four internationally recognised 
institutions that share research interests, expertise in 
effective interventions in psychotic disorders, strategic 
vision to reduce the burden of psychotic disorders in 
resource- poor settings and who are keen to expand their 
research knowledge to implement evidence- based clin-
ical changes in LMIC settings. Informed by principles of 
evidence- based EIS developed in the UK and Canada, the 
WIC GHRG will develop culturally sensitive interventions 
that will expand mental health services to communities 
that currently have limited access in India. WIC will also 
build and sustain much- needed research capacity and 
support the implementation of evidence- based practice.
The Indian context
India with its 1.3 billion population has a severe shortage 
of mental healthcare provision. Compared with a global 
average of 3.96 psychiatrists/100 000 population, India 
has 0.75 psychiatrists/100 000 population. The overall 
availability of mental healthcare workers (psychiatrists, 
clinical psycologists and psychiatric social workers) is 
<1/100 000 population.19 20 India therefore has a large 
number of patients with undetected, untreated or inade-
quately treated psychotic disorders.21 Even when patients 
access care, there is no continuity; treatment is sporadic 
and focused on symptomatic control and crisis manage-
ment rather than recovery.22 Social stigma and discrim-
ination associated with mental illness are also major 
impediments to delivering evidence- based care.23 Studies 
have found that many prodromal patients (‘at- risk’ 
for psychosis) remain undetected in the community,24 
and there are few early identification programmes in 
operation.
Objectives
The key objectives of WIC are the following:
1. To develop a culturally tailored FEP management 
protocol, based on evidence synthesis of current clin-
ical practice at partner sites and by modifying proto-
col from the National Evaluation of Development of 
Early intervention Network (NEDEN) study, to make 
sustained health improvements for poorly served indi-
viduals with FEP.
2. To better understand pathways of care to develop im-
proved early detection strategies for psychosis relevant 
to India.
3. To create a data set of well- characterised inception co-
horts of FEP with research- ready systems and processes 
that will enable to answer new research questions.
4. To investigate clinical effectiveness and cost- 
effectiveness of innovative community care models for 
psychosis, including digital and mobile applications.
5. To develop and implement school- based and college- 
based intervention programmes for early detection 
and referral of individuals with psychosis.
6. To build research capacity by providing a strong mul-
tidisciplinary research and training programme for re-
searchers based in India.
A larger goal is to build strong research collaborations 
between India, UK and Canada partners for long- term 




The design of WIC programme is depicted in figure 1. 
Our strategic plan comprises five work packages (WPs) 
and two cross- cutting themes (CTs) with clear objectives 
and deliverables. In addition, we will exploit the poten-
tial of digital/mobile technologies to (1) identify mental 
disorders in students and (2) increase access to clin-
ical services and continuity of care for difficult- to- treat 
cases of schizophrenia. The study will be conducted in 
accordance with ethical principles that comply with the 
Declaration of Helsinki and the International Council 
on Harmonisation’s Harmonised Tripartite Guideline 
for Good Clinical Practice (GCP). All participants will 
provide written informed consent or parental assent prior 
to entering a study.
WIC programme—management
The University of Warwick is the sponsor organisation. 
A programme manager (PM) is responsible for the day- 
to- day management of the research programme and 
supports the GHRG director for the overall delivery of the 
research programme. The PM, GHRG director and WP 
leads are responsible for the overall management of the 
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study and meet monthly by video conference chaired by 
the director. The programme steering committee (PSC), 
comprising PM, GHRG director, co- investigators and WP 
leads, provides overall strategic direction, ensures good 
governance, provides scientific input, guides capacity- 
building activities and provides financial probity when 
required. An independent external scientific advisory 
group (ESAG) comprising five international experts 
will monitor and assess the study conduct and progress. 
Both PSC and ESAG meet annually with the consortium 
to assess the scientific quality of research and to give 
feedback.
Study sites
WIC brings together four institutions: University of 
Warwick, UK; McGill University, Canada; All India Insti-
tute of Medical Sciences (AIIMS), New Delhi, India; and 
Schizophrenia Research Foundation (SCARF), Chennai, 
India. SCARF, based in Chennai, is a non- profit voluntary 
organisation providing care to patients with psychosis and 
a WHO- collaborating centre for schizophrenia research. 
With a population of over 7 million, Chennai is the fourth 
largest metropolis in India. AIIMS, based in New Delhi 
with its metropolitan area population of 30 million, is a 
tertiary care hospital involved in providing undergrad-
uate and postgraduate medical education and research, 
and hosts the National Drug Dependence Treatment 
Centre, a WHO- collaborating centre.
WP1: partnerships, collaborations and stakeholder engagement
In WP1, we developed a network of external stakeholders 
in youth mental health including user and carer advocacy 
groups, clinicians, academicians and policy- makers, and it 
will be conducted at both study sites. A situational analysis 
and needs analysis were conducted to identify user and 
carer priorities, barriers to help- seeking and modifiable 
aspects of care pathways. ‘Therapeutic ingredients’ of 
early intervention that can be introduced in clinical care 
in India will be identified. The results from this WP have 
been published elsewhere.25 26
WP2: protocol-based assessment and management of FEP
Using the insights from WP1 and evidence- based inter-
ventions developed in the UK and Canada for EIS, in 
WP2 we will adapt protocols from the UK NEDEN study,27 
the largest FEP cohort in the world, to gather FEP cases at 
both SCARF and AIIMS, ensuring valid and reliable trans-
lation of assessment tools. A comphrehensive package of 
biopsychosocial care, tailored to the local context, will be 
developed and delivered to all new FEP cases and their 
short- term and medium- term outcomes measured. An 
FEP patient registry (comprising both affective and non- 
affective psychosis) will be maintained at our study sites. 
The study population, study assessment tools and study 
assessment schedules are described in Section A in the 
online supplemental material.
WP3: understanding pathways to care
The objective of WP3 is to determine pathways to care 
in FEP at both sites, using a combination of qualitative 
and quantitative approaches. We will explore DUP and 
its components (help- seeking delay, treatment delay 
following presentation), cultural attribution of psychosis 
symptoms (eg, individual, supernatural), help- seeking 
behaviour and modifiable factors that contribute to 
DUP. We will exploit the established methodology for 
case ascertainment and care pathways from the NIHR 
ENRICH Programme.28 We will examine the following 
questions:
1. Do the two cohorts (South India vs North India) dif-
fer significantly in culturally mediated illness attribu-
tions (ie, individual, natural, social, supernatural and 
no attribution) during FEP? The cohorts vary demo-
graphically and in terms of study setting (outpatient 
non- governmental organisation in South India vs large 
Figure 1 Schematic overview of Warwick- India- Canada Global Health Research Group. AIIMS, All India Institute of Medical 
Sciences; FEP, first episode of psychosis; SCARF, Schizophrenia Research Foundation.
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general hospital with emergency, inpatient and outpa-
tient facilities in North India).
2. Do the two cohorts differ in their pathways to care (ie, 
DUP, compulsory detention, psychiatrists, emergency 
services, general practitioner, faith- based organisa-
tions) during FEP?
3. Are the pathways to care during FEP influenced by cul-
turally mediated illness attributions and other relevant 
sociodemographic (ie, gender, religious practice, mar-
ital status, living alone, education, income) and clini-
cal confounders such as DUP?
Study setting, population and study assessment tools
This study will be conducted at SCARF, Chennai, and 
AIIMS, New Delhi, using the data sets collected from FEP 
patients recruited as part of WP2. The study instruments 
that will be used in this study are (1) the Emerging Psychosis 
Attribution Schedule,29 (2) Nottingham Onset Schedule30 
and (3) an amended version of the Encounter form by 
Gater and Sousa.29
WP4: mobile technology to ensure continuity of care
Globally, India has the second largest number of mobile 
phone users—900 million users accounting for 88% of 
all telecommunication users.31 Studies have emerged 
from high- income countries on mobile technologies in 
psychosis32 but are lacking in LMICs.33 Our preliminary 
survey shows that 88% of patients have mobile phones.34 
The objective of WP4 is to develop a home- based psycho-
social care model for ‘difficult- to- treat’ patients with 
schizophrenia aimed at functioning and recovery, and 
an associated mobile- based application. In the absence 
of state provision in India, mobile- based clinical care 
has the potential to facilitate appropriate clinical care. 
In this WP, we will compare and evaluate the feasibility 
and effectiveness of a paper version of the model with the 
mobile app in improving patient outcomes and reducing 
carer burden. This study will be conducted at AIIMS, 
New Delhi. The study population, inclusion/exclusion 
criteria, methodology, assessment tools and study assess-
ment schedules are described in Section B of the online 
supplemental material.
WP5: early detection using a community awareness programme
The primary aim of WP5 is to develop and implement 
a school- based and college- based intervention for early 
detection and referral of individuals with emerging 
mental health problems. We wish to pilot a school- based 
and college- based programme of online screening for 
emerging mental health problems, assess the effectiveness 
of using community resources (teachers, peers and youth 
groups) to provide psychosocial intervention and deter-
mine the clinical effectiveness and cost- effectiveness of 
the screening programme. This study will be conducted by 
SCARF in Chennai, India. The identified catchment area 
for the study is Anna Nagar, Chennai, and the adjacent 
areas have 14 schools and 4 colleges. Informed consent 
from the management of the educational institutions will 
be sought before conducting the study at their institu-
tion. The study assessment tools and study intervention 




Despite being the first LMIC to introduce a National 
Mental Health Programme, there remains a significant 
implementation gap in the delivery of evidence- based 
interventions for mental healthcare in India.35 36 Imple-
mentation science represents an approach focused on 
understanding the challenges, identifying the barriers and 
harnessing facilitators to help translate research- based 
evidence to ‘real- world’ clinic and community settings, 
developing leadership and changing professional prac-
tice to support delivery of evidence- based innovation.37
The primary objective of this study is to evaluate the 
implementation of the EIS in India. We will address the 
implementation barriers and facilitators in healthcare 
according to the Consolidated Framework for Implemen-
tation Research.38 Our specific aims are (1) to identify 
barriers and facilitators to implementation, sustaining 
(beyond pilot) and scaling up of evidence- based early 
intervention to address psychosis and (2) to assess how 
the original intervention is adapted to fit context and to 
what extent it then diverges from its original evidence 
base. The study will be carried out at SCARF, Chennai.
Health economics
The primary objective of the health economics theme 
is to assess the cost of treatment for patients with FEP 
attending AIIMS from the payer and provider perspec-
tive. We will develop and pilot a questionnaire to deter-
mine direct and indirect costs experienced by patients 
with mental illness, and their households, and the coping 
strategies used in response to these costs. From these 
data, we will estimate mean, median and quartile costs at 
each time point. We will also conduct a bottom- up costing 
of the typical package of care offered to those partici-
pating in WP2 at AIIMS. This will be based on unit cost 
data collected during the study, along with interviews with 
clinicians taking part in the study on the care delivered 
and the time taken to deliver it.
Capacity-building activities
There is an urgent need to develop and deliver high- 
quality research on capacity- building activities in India, 
ranging from modules on research methodology to 
doctoral- level training and courses aimed at healthcare 
and leadership.
PhDs
WIC, along with TATA Trust, India, and Warwick Medical 
School, is supporting three PhD candidates from India 
at the University of Warwick by enabling them to carry 
out their primary research activities in their home coun-
tries. These three students, who were selected after a 
competitive process, commenced their doctoral studies 
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in May 2019. The PhD topics included projects that are 
nested within WIC and stand- alone projects that are 
closely aligned to the WIC research priorities. At least two 
University of Warwick- based supervisors and one partner 
country- based supervisor are allocated to each student for 
their PhDs. Topics approved for the first cohort of WIC 
PhD students include (1) health economics, (2) pathways 
of care and service engagements in early intervention 
services and (3) assessing factors associated with hospital 
readmissions and strategies to reduce the burden of read-
missions in psychiatric hospitals in India.
Research leadership training programme
At Warwick Business School, we already have an interna-
tional distance- learning Leadership Development Programme 
for clinicians, with case studies from Africa and South 
East Asia. We will develop a contextualised distance- 
learning intervention about leadership and innovation 
for mental health professionals in India. This innovative 
training will be focused on developing another case from 
the WIC programme, specific to youth mental health in 
India. Integrating leadership and innovation training in 
clinical and service development domains will be benefi-
cial for mental health professionals, particularly in formu-
lating clinical priorities and engaging meaningfully with 
policy- makers in the country.
Planned extensions
The WIC GHRG has secured funding from NIHR to 
conduct an additional programme of work, which builds 
on the existing programme of work, for a duration of up 
to 12 months. In this costed extension programme, we 
will (1) extend our current school- based screening for 
mental disorders (WP5) in two vulnerable populations: 
(a) refugee youth (Jammu & Kashmir) and (b) a high- 
risk tribal population in Mahrashtra; (2) expand our FEP 
registry (WP2) to a rural setting (Nagpur), for potential 
comparisons with other sites and with existing data sets 
and including additional research questions of interest 
(such as cardiometabolic parameters, lifestyle interven-
tions); (3) extend health economic analysis to include 
rural populations and explore how financial burden 
and coping mechanisms differ between settings; and (4) 
develop a research- based leadership training programme.
Analysis plan
For WP1, a prospective cross- sectional study in the form 
of a situational analysis and needs assessment with mental 
health professionals and external stakeholders will be 
conducted to capture information on current practices 
and available resources for the management of FEP. A 
semistructred pro forma will be developed to capture 
quantitative and qualitative data on facilities available 
for FEP management at each health centres, pharma-
cological and non- pharmacological management, local 
training needs, hospitalisation data and follow- up data 
of FEP cases. The data will be analysed using standard 
summary statistical methods, with indicators of variability, 
central tendency, frequency, percentage, ratio or propor-
tion, as appropriate
For the remaining WPs and CTs, we will use standard 
descriptive statistical methods to evaluate the data. Where 
appropriate, continuous variables will be assessed for 
normality, and non- normally distributed variables will 
be transformed or assessed using non- parametric tests as 
appropriate. To compare the data (eg, sociodemographic 
and clinical factors) between and within study sites, we will 
use independent- samples t- tests for continuous variables 
and χ2 for dichotomous variables (WP2 and WP3). To 
assess the change in several domains of symptom severity 
and functioning at prespecified time points, we will use 
a general linear modelling analysis, adjusting for various 
potential confounders (eg, WP2, WP4). We will use test- 
adjusted and test- unadjusted associations using statistical 
tests as appropriate (eg, WP3). For unadjusted analysis, 
we will use (1) analysis of variance for testing unadjusted 
associations between ethnic groups and culturally medi-
ated illness attributions and service encounters (normally 
distributed continuous outcomes), (2) Kruskal- Wallis 
rank- sum tests (for non- normally distributed contin-
uous outcomes) and (3) logistic regression for dichoto-
mous variables. For adjusted association analysis, we will 
use multiple logistic regression analysis, controlling for 
various confounders of interest. To provide informa-
tion regarding the magnitude of the change in scores in 
domains of interest (eg, WP5), Cohen’s d effect sizes will 
be calculated with effect size values of ≥0.5, ≥0.8 and ≥1.0 
corresponding to moderate, large and very large effect, 
respectively (eg, WP5). For CTs such as implementa-
tion science and health economics, we will use standard 
descriptive statistics to describe the data and framework 
analysis (implementation science), if deemed necessary.
Statistical significance will be inferred at p<0.05. We will 
consider sensitivity to change as adequate, if the improve-
ment is statistically significant (p<0.05) and with at least 
a moderate effect size (Cohen’s d ≥0.50). The primary 
analysis will be undertaken by excluding patients with 
missing data. However, we will conduct sensitivity anal-
ysis for missing data using the following imputation tech-
niques, as appropriate: (1) last value carried forward, (2) 
baseline value carried forward, (3) single imputation with 
expectation–maximisation algorithm and (4) multiple 
imputation. Data will be analysed using appropriate statis-
tical software (eg, SPSS, R, STATA).
Assuring instrument reliability
Clinical instruments requiring ratings by research 
staff will continue to be tested for inter- rater reliability 
across the two sites, SCARF and AIIMS. A joint meeting 
of the research staff from both sites was held and inter- 
rater reliability exercises on the important measures 
were conducted using video- recorded interviews with 
10 randomly selected patients with FEP. Data were 
successfully collected for the following measures: Scale 
for Assessment of Positive Symptoms, Scale for Assess-
ment of Negative Symptoms, Young Mania Rating Scale, 
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Montgomery-Åsberg Depression Rating Scale, Brief 
Psychiatric Rating Scale, Global Assessment of Func-
tioning, Social and Occupational Functioning Assess-
ment Scale and Medication Adherence Rating Scale. A 
high degree of inter- rater reliability across sites (intraclass 
correlations from 0.74 to 0.92) was obtained on these 




Written informed consent will be obtained from all partic-
ipants or carers as appropriate, before their enrolment 
into the study. In the school- based and college- based study 
(WP5), all participants will receive information on where 
to seek help for mental health problems. In addition, we 
have developed a clinical care pathway for those who are 
identified as being at ‘high risk’ for severe mental illness 
or having undetected/untreated severe mental illness 
or with suicidal ideations that will ensure safety, protec-
tion of confidentiality and privacy. The study principal 
investigator and team will preserve the confidentiality 
and anonymity of participants taking part in the study 
and fulfil transparency requirements under the General 
Data Protection Regulation for health and care research. 
The study may be subject to inspection and audit by the 
University of Warwick under their remit as sponsor and 
other regulatory bodies to make sure of adherence to 
GCP and the UK Policy Framework for Health and Social 
Care Research.
This study has been approved by the University of 
Warwick’s Biomedical and Scientific Research Ethics 
Committee (reference: REGO-2018-2208), Coventry, UK 
and research ethics committees of all participating organ-
isations. The ethical conduct of the study is monitored 
throughout by the University of Warwick and each partic-
ipating organisation.
Dissemination strategies
We will strategically exploit our strong network with 
various LMIC stakeholders involved in mental health 
services such as clinicians, academics, service providers, 
policy- makers, government and non- governmental agen-
cies, community groups, patient and carer advocacy 
groups, media agencies and the creative arts industry 
to support WIC dissemination activities. We will use a 
variety of methods to ensure effective dissemination of 
the groups’ work, including (1) development of an up- to- 
date project website (to target different audiences/stake-
holders); (2) presentations at national and international 
psychiatric and mental health scientific conferences, and 
peer review publications; and (3) publication through 
visual media including film and theatre. Dissemination 
activities through cinema and theatre have a particular 
resonance for many LMIC populations, and we believe 
that we will reach a large number of people through these 
activities. We will work closely with our LMIC partners to 
identify the dissemination approaches that might work 
best in this setting.
Patient and public involvement
We have strong and ongoing engagement with various 
internal and external stakeholders involved in mental 
healthcare. The WP1 of WIC uses focus groups as a 
method for situational analysis and needs analysis and 
will include patients and carer groups, and voluntary/
charity/third- sector organisations, ensuring represen-
tation of hard- to- reach groups. Patient and/or public 
groups were not involved in proposing the research objec-
tives nor were involved in the overall study design or the 
implementation of this research programme. However, 
stakeholders involved in mental health will be engaged 
by the research team at respective sites as local dissemi-
nation plans are being devised. All partners also have an 
extensive record of patient and public involvement (PPI) 
in research. We have a robust programme for monitoring 
and governance—research, ethics, and financial, and our 
programme will adhere to the highest levels of ethical 
practice and probity including PPI involvement.
CONCLUSION
Although major improvements have been achieved in the 
treatment of patients with psychotic disorders in high- 
income countries, including the wide- scale implemen-
tation of EIS in psychosis, implementing such services 
remains a major challenge in LMICs. The sizeable differ-
ences in patient profiles, sociodemographics, pathways of 
care, barriers to care, comorbidities, scarcity of resources 
and delayed presentation mean, at the very least, Western 
models of care cannot be simply translocated to LMICs. 
The WIC programme will tailor evidence- informed inter-
ventions to the Indian sociocultural context to address 
the increasing burden of psychotic disorders in India. By 
using a bespoke interventional approach that is region-
ally relevant and by exploiting the untapped potential 
of digital and mobile technologies in India, WIC will 
develop and test interventions that can be integrated into 
existing clinical care and generate data (including health 
economic data) that will inform priorities for healthcare 
providers and policy- makers.
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